JOP20210147A1 - صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه - Google Patents

صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Info

Publication number
JOP20210147A1
JOP20210147A1 JOP/2021/0147A JOP20210147A JOP20210147A1 JO P20210147 A1 JOP20210147 A1 JO P20210147A1 JO P20210147 A JOP20210147 A JO P20210147A JO P20210147 A1 JOP20210147 A1 JO P20210147A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical compositions
crystalline
organic compound
salts
salt forms
Prior art date
Application number
JOP/2021/0147A
Other languages
English (en)
Inventor
Syed Altaf
Shijie Zhang
Abira Ramakrishnan
Jacob Sizemore
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of JOP20210147A1 publication Critical patent/JOP20210147A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOP/2021/0147A 2018-12-21 2019-12-20 صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه JOP20210147A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
JOP20210147A1 true JOP20210147A1 (ar) 2023-01-30

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0147A JOP20210147A1 (ar) 2018-12-21 2019-12-20 صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Country Status (20)

Country Link
US (1) US20220055995A1 (ar)
EP (1) EP3898597A1 (ar)
JP (1) JP2022515239A (ar)
KR (1) KR20220035022A (ar)
CN (1) CN113508108A (ar)
AU (1) AU2019403396A1 (ar)
BR (1) BR112021012305A2 (ar)
CA (1) CA3124401A1 (ar)
CL (1) CL2021001640A1 (ar)
CO (1) CO2021009309A2 (ar)
CR (1) CR20210394A (ar)
IL (1) IL284218A (ar)
JO (1) JOP20210147A1 (ar)
MA (1) MA54541A (ar)
MX (1) MX2021007536A (ar)
NI (1) NI202100055A (ar)
PE (1) PE20212197A1 (ar)
SG (1) SG11202106526UA (ar)
TW (1) TW202039448A (ar)
WO (1) WO2020132471A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755324A1 (en) 2018-02-20 2020-12-30 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US20230285365A1 (en) 2020-08-27 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) * 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Also Published As

Publication number Publication date
WO2020132471A8 (en) 2020-08-06
AU2019403396A1 (en) 2021-07-08
CN113508108A (zh) 2021-10-15
JP2022515239A (ja) 2022-02-17
KR20220035022A (ko) 2022-03-21
CL2021001640A1 (es) 2022-06-03
TW202039448A (zh) 2020-11-01
BR112021012305A2 (pt) 2021-10-05
NI202100055A (es) 2021-12-01
IL284218A (en) 2021-08-31
SG11202106526UA (en) 2021-07-29
MA54541A (fr) 2022-03-09
US20220055995A1 (en) 2022-02-24
PE20212197A1 (es) 2021-11-16
WO2020132471A1 (en) 2020-06-25
CA3124401A1 (en) 2020-06-25
CR20210394A (es) 2021-12-13
EP3898597A1 (en) 2021-10-27
CO2021009309A2 (es) 2021-10-29
MX2021007536A (es) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2021003460A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690094A1 (ru) Ингибиторы syk
EA201890752A1 (ru) Способ получения противогрибковых соединений
MX2023001876A (es) Derivados de rapamicina.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA201990833A1 (ru) Соединение пиридина
EA201891553A1 (ru) Ингибиторы syk
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2018006390A (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
CR20210394A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов